Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment.

J Am Heart Assoc · 2026 · PMC13279106 · PMID 42017316

Europe PMC DOI

hedged sentences

0.1520

closest p · 3.0× alpha

0.1520

boldest claim

The sentences

did not reach statistical significanceP =0.152not close (p > 0.1)

However, this result did not reach statistical significance (HR, 0.74; 95% CI, 0.49–1.12; P =0.152, Table 4 ).

also in 111,027 other papers

showed a trendno p-value reported

Compared with alirocumab, statins showed a trend toward reduced risk of the primary composite outcome, which included cardiovascular death, MI, HF, stroke, and coronary revascularization.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.